1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)

Technology appraisal [TA674] Published date: 17 February 2021

  • Guidance
  • Tools and resources
  • Evidence

Tools and resources

Tools to help you put the guidance into practice.

Guidance into practice

  • About the Into practice guide  
  • Practical steps to improving the quality of care and services using NICE guidance